| Date Filed | Type | Description |
| 10/03/2023 |
4
| Loeillot Olivier (President and CCO) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Granted 12,906 shares
@ $0
Granted 24,236 options to buy
@ $154.96, valued at
$3.8M
|
|
| 10/03/2023 |
3
| Loeillot Olivier (President and CCO) has filed a Form 3 on REPLIGEN CORP |
| 10/02/2023 |
8-K
| Quarterly results |
| 09/27/2023 |
4
| Garland Jason K (CFO) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Granted 5,503 shares
@ $0
Granted 10,524 options to buy
@ $158.99, valued at
$1.7M
|
|
| 09/27/2023 |
3
| Garland Jason K (CFO) has filed a Form 3 on REPLIGEN CORP |
| 08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/02/2023 |
8-K
| Quarterly results |
| 05/22/2023 |
4
| Madaus Martin D (Director) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Granted 686 shares
@ $0
Granted 1,487 options to buy
@ $156.63, valued at
$232.9k
|
|
| 05/22/2023 |
4
| Mhatre Rohin (Director) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Granted 686 shares
@ $0
Granted 1,487 options to buy
@ $156.63, valued at
$232.9k
|
|
| 05/22/2023 |
4
| DAWES KAREN A (Director) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Granted 798 shares
@ $0
Granted 1,730 options to buy
@ $156.63, valued at
$271k
|
|
| 05/22/2023 |
4
| EGLINTON MANNER CARRIE (Director) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Granted 686 shares
@ $0
Granted 1,487 options to buy
@ $156.63, valued at
$232.9k
|
|
| 05/22/2023 |
4
| BARTHELEMY NICOLAS (Director) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Granted 686 shares
@ $0
Granted 1,487 options to buy
@ $156.63, valued at
$232.9k
|
|
| 05/22/2023 |
4
| MUIR GLENN P (Director) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Granted 686 shares
@ $0
Granted 1,487 options to buy
@ $156.63, valued at
$232.9k
|
|
| 05/22/2023 |
4
| Konstantinov Konstantin (Director) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Granted 686 shares
@ $0
Granted 1,487 options to buy
@ $156.63, valued at
$232.9k
|
|
| 05/16/2023 |
4
| KURIYEL RALF (Senior VP, R&D) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Paid exercise price by delivering 710 shares
@ $154.03, valued at
$109.4k
|
|
| 05/16/2023 |
4
| Gebski Christine (See Remarks) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Paid exercise price by delivering 334 shares
@ $154.03, valued at
$51.4k
|
|
| 05/16/2023 |
4
| Snodgres Jon (CFO) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Paid exercise price by delivering 710 shares
@ $154.03, valued at
$109.4k
|
|
| 05/08/2023 |
4
| Madaus Martin D (Director) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Small acquisition of 11 shares
@ $186.22, valued at
$2k
Bought 500 shares
@ $161.15, valued at
$80.6k
Bought 500 shares
@ $159.19, valued at
$79.6k
Bought 500 shares
@ $156.18, valued at
$78.1k
|
|
| 05/05/2023 |
3/A
| Madaus Martin D (Director) has filed a Form 3/A on REPLIGEN CORP |
| 05/02/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/02/2023 |
8-K
| Quarterly results |
| 04/18/2023 |
8-K
| Quarterly results |
| 04/04/2023 |
4
| Bylund James (COO) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Paid exercise price by delivering 334 shares
@ $163.45, valued at
$54.6k
|
|
| 03/24/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/06/2023 |
4
| Snodgres Jon (CFO) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Granted 4,848 shares
@ $0
Granted 8,795 shares
@ $0
Paid exercise price by delivering 3,674 shares
@ $188, valued at
$690.7k
Granted 5,019 options to buy
@ $180.48, valued at
$905.8k
|
|
| 03/06/2023 |
4
| KURIYEL RALF (Senior VP, R&D) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Granted 3,468 shares
@ $0
Granted 3,591 shares
@ $0
Paid exercise price by delivering 1,247 shares
@ $188, valued at
$234.4k
Granted 3,591 options to buy
@ $180.48, valued at
$648.1k
|
|
| 03/06/2023 |
4
| Gebski Christine (See Remarks) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Granted 3,467 shares
@ $0
Granted 375 shares
@ $0
Paid exercise price by delivering 126 shares
@ $188, valued at
$23.7k
Granted 3,590 options to buy
@ $180.48, valued at
$647.9k
|
|
| 03/06/2023 |
4
| Hunt Anthony (CEO) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Granted 19,393 shares
@ $0
Granted 18,584 shares
@ $0
Paid exercise price by delivering 8,244 shares
@ $188, valued at
$1.5M
Granted 20,080 options to buy
@ $180.48, valued at
$3.6M
|
|
| 03/06/2023 |
4
| Bylund James (COO) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Granted 8,348 shares
@ $0
Granted 625 shares
@ $0
Paid exercise price by delivering 210 shares
@ $188, valued at
$39.5k
Granted 8,644 options to buy
@ $180.48, valued at
$1.6M
|
|
| 03/02/2023 |
4
| Hunt Anthony (CEO) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Paid exercise price by delivering 2,748 shares
@ $173.28, valued at
$476.2k
Paid exercise price by delivering 6,670 shares
@ $176.37, valued at
$1.2M
|
|
| 03/02/2023 |
4
| Gebski Christine (See Remarks) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Paid exercise price by delivering 460 shares
@ $173.28, valued at
$79.7k
Paid exercise price by delivering 630 shares
@ $174.37, valued at
$109.9k
|
|
| 03/01/2023 |
4
| KURIYEL RALF (Senior VP, R&D) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Paid exercise price by delivering 358 shares
@ $173.28, valued at
$62k
|
|
| 03/01/2023 |
4
| Snodgres Jon (CFO) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Paid exercise price by delivering 521 shares
@ $173.28, valued at
$90.3k
|
|
| 02/28/2023 |
4
| Bylund James (COO) has filed a Form 4 on REPLIGEN CORP|
Txns:
| Paid exercise price by delivering 594 shares
@ $173.44, valued at
$103k
|
|
|